Strategic Partnerships Northway Biotech actively collaborates with preclinical-stage biotech companies such as Diorasis Therapeutics, Kaida Biopharma, and Micreos Pharmaceuticals to develop and manufacture innovative gene and biologic therapies, opening opportunities to offer scalable GMP manufacturing and process development services to similar early-stage biotech clients.

Expanding Service Offerings The recent launch of VCS with BSL-2 and BSL-3 labs enhances Northway’s capabilities in handling high-containment biological projects, providing sales prospects in advanced biosafety level environments for clients working on high-risk therapies and vaccines.

Focus on Gene Therapies Ongoing development of AAV-based gene therapies and partnerships for scalable cGMP production highlight a strong market focus on gene therapy manufacturing, creating opportunities to target pharmaceutical firms advancing gene-based treatments.

Innovation and Flexibility Northway’s ability to react rapidly to project changes and its comprehensive range of development and manufacturing services position it as a preferred partner for biotech companies needing flexible, high-quality solutions across the biopharmaceutical value chain.

Growing Market Presence With a revenue range of $10M to $25M and expanding collaborations within the biotech industry, Northway Biotech is positioned for growth, offering a compelling value proposition for clients seeking reliable, innovative CDMO services in the thriving biopharmaceutical sector.